L3VLUP
ProSign in

BHC · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BHCJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BHC
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBHCJNJ
Q3 202010 holders, $664m30 holders, $26.2bn
Q4 202011 holders, $1.0bn32 holders, $26.6bn
Q1 202112 holders, $2.3bn31 holders, $25.3bn
Q2 202114 holders, $2.2bn37 holders, $25.6bn
Q3 202110 holders, $2.0bn40 holders, $24.1bn
Q4 20219 holders, $1.8bn33 holders, $25.2bn
Q1 202213 holders, $1.5bn35 holders, $28.2bn
Q2 20228 holders, $539m33 holders, $26.9bn
Q3 202210 holders, $350m36 holders, $25.4bn
Q4 20229 holders, $325m35 holders, $27.6bn
Q1 20235 holders, $387m42 holders, $24.5bn
Q2 20236 holders, $409m38 holders, $25.0bn
Q3 20239 holders, $429m37 holders, $18.9bn
Q4 20236 holders, $403m31 holders, $19.0bn
Q1 20249 holders, $594m32 holders, $19.7bn
Q2 20248 holders, $380m35 holders, $20.4bn
Q3 20246 holders, $331m28 holders, $22.3bn
Q4 20246 holders, $341m37 holders, $20.4bn
Q1 20255 holders, $277m32 holders, $20.5bn
Q2 20255 holders, $285m31 holders, $18.4bn
Q3 20254 holders, $47m32 holders, $23.7bn
Q4 20256 holders, $68m29 holders, $27.8bn
Q1 20265 holders, $61m34 holders, $35.6bn
Q2 20264 holders, $55m33 holders, $39.1bn
BHC

Bausch Health Cos Inc

Holders
9
Reported value
$594m
Buyers
3
Sellers
3

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BHC (4)

Carl C. Icahn, Elliott Investment Management LP, Oaktree Capital Management LP, Rokos Capital Management LLP

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Walleye Capital LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →